



April 15, 2022

**BSE Limited**

Floor 25, P. J. Towers  
Dalal Street, Fort  
Mumbai - 400 001

**National Stock Exchange of India Limited**

Exchange Plaza  
Bandra Kurla Complex  
Bandra (E), Mumbai - 400 051

Dear Sirs,

Pursuant to Regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose a copy of Press Release/Communication being issued by the Company pertaining to winning a contract under its CDMO business with one of its customer, who is a global pharmaceutical innovator company.

We request you to take the same on records.

Thanking you,

Yours faithfully,  
For Jubilant Ingrevia Limited

Deepanjali Gulati  
Company Secretary

Encl.: as above

A Jubilant Bhartia Company

OUR VALUES



**Jubilant Ingrevia Limited**

1-A, Sector 16-A,  
Noida-201 301, UP, India  
Tel: +91 120 4361000  
Fax: +91 120 4234895-96  
[www.jubilantingrevia.com](http://www.jubilantingrevia.com)

Regd Office:  
Bhartiagram, Gajraula  
Distt. Amroha - 244 223  
Uttar Pradesh, India  
CIN : L24299UP2019PLC122657



**Jubilant Ingrevia Limited**  
1A, Sector 16A, Noida – 201301, India  
Tel.: +91 120 4361000  
[www.jubilantingrevia.com](http://www.jubilantingrevia.com)

## Press Release

---

# Jubilant Ingrevia Limited augments its CDMO presence with ~INR 270 Crore contract

## STRENGTHENS RELATIONSHIP WITH KEY PHARMACEUTICAL INNOVATOR THROUGH TWO GMP INTERMEDIATES

---

**Noida, India, April 15, 2022:** Jubilant Ingrevia Limited (Company), a global integrated Life Science products and Innovative Solutions provider with over 42 years of experience offering over 165 products & innovative solutions using more than 35 key chemistry and technology platforms across its three portfolio of businesses viz Acetyls, Pyridines and Vitamins & Premixes, today announced a **CDMO contract for estimated value of Rs 270 Crore in Specialty Chemicals business, spanning over a period of three years with one of its international customers, who is among the top 10 leading innovator pharmaceutical companies globally.**

Through the contract the Company will supply **Two key GMP intermediates for one of the ‘patented drugs’ of the Innovator Pharmaceutical customer.** Both these products involve 7 steps specialised chemistry. **The Company was awarded these CDMO projects few years back and with extensive work in R&D and Scale-up, it has successfully demonstrated its capability in Process development, optimisation and scaling-up of complex chemistries.** Commercial supplies of both these products will start from FY’23 onwards. The Company will use GMP facility to service this contract.

**Speaking on the occasion, Mr. Rajesh Srivastava, CEO & Managing Director, Jubilant Ingrevia Limited shared,** *“The pursuit of growth is one of the key features of our strategy. Today’s announcement is in line with our strategy & commitment to grow our CDMO business of value-added GMP & Non GMP intermediates. Success of these two GMP intermediates further demonstrates our capabilities to successfully develop and commercialise cost-effective processes with excellent quality involving complex chemistries. Our CDMO project pipeline for our Pharmaceuticals & Agrochemical continues to be strong and we stay committed to further strengthen our presence in the CDMO business, through a comprehensive and planned capex.”*

---

## **About Jubilant Ingrevia Limited**

*Jubilant Ingrevia Limited is a global integrated Life Science products and Innovative Solutions provider serving Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers with customised products and solutions that are innovative, cost-effective and conforming to excellent quality standards.*

*The Company offers a broad portfolio of high quality ingredients that find application in a wide range of industries. The company has 2,100 employees and serves more than 1,400 customers in more than 50 countries across the world. The Company's portfolio also extends to custom research and manufacturing for pharmaceutical and agrochemical customers on an exclusive basis.*

*Jubilant Ingrevia is a Responsible Care certified company, driven by the motive to add value to millions of lives through innovations and cutting-edge technology. As a leader in key products that the Company manufactures, it takes pride in being a partner of choice for its valued customers. For more information, please visit: [www.jubilantingrevia.com](http://www.jubilantingrevia.com).*

---

### **For more information, please contact:**

---

*For Investors:*

*Pavleen Taneja*

*Jubilant Ingrevia Limited*

*Ph: +91-120 436 1000*

*E-mail: [pavleen.taneja@jubl.com](mailto:pavleen.taneja@jubl.com)*

*Siddharth Rangnekar / Karl H Kolah*

*CDR India*

*Ph: +91 97699 19966 / 98330 10478*

*E-mail: [siddharth@cdr-india.com](mailto:siddharth@cdr-india.com)  
[karl@cdr-india.com](mailto:karl@cdr-india.com)*

*For Media & Press:*

*Sudhakar Safaya*

*Ph: +91 120 436 1062*

*E-mail: [sudhakar.safaya@jubl.com](mailto:sudhakar.safaya@jubl.com)*

*Clayton Dsouza*

*Madison Public Relations*

*Ph: +91 9930011602*

*E-mail: [clayton.dsouza@madisonpr.in](mailto:clayton.dsouza@madisonpr.in)*

**Disclaimer:** *Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Ingrevia Limited may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and our reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.*

---